https://pharmasprings.com/ijcpms/issue/feed International Journal of Clinical Pharmacokinetics and Medical Sciences 2024-11-29T16:15:13+0530 Editor editorijcpms@pharmasprings.com Open Journal Systems <div> <img style="width: 100%;" src="https://pharmasprings.com/templates/frontend/pages/slideshow/slideshow2.gif" /></div> <p align="justify">International Journal of Clinical Pharmacokinetics and Medical Sciences <em>(IJCPMS)</em> ISSN: 2583-0953 is established in the year 2021 officially sponsored by <em><strong>pharma springs publication</strong></em>. We are pleased to introduce ourselves as the novel imminent, and sovereign online pharmacy &amp; medical information services in India. The foundation aims to serve as a means for updating the scientific knowledge of the international audience in the research field of science so a correlation can be made between these researchers. IJCPMS will be published quarterly per year in March, Jun, September, and December. The journal publishes the work that contributes significantly to further the scientific knowledge in the areas of pharmaceutical, medical &amp; biological sciences. All contributions to the journal are rigorously refereed and are selected based on the quality and originality of the work.</p> https://pharmasprings.com/ijcpms/article/view/671 A review on triggering factors and causes of infertility 2024-11-29T16:15:13+0530 Dr Salma Shaik syedabusalma.shaik@gmail.com S. Jaya Chandra syedabusalma.shaik@gmail.com M. Leelavathi syedabusalma.shaik@gmail.com G. Rajesh syedabusalma.shaik@gmail.com Dr. N. Muthu Rani syedabusalma.shaik@gmail.com Dr. S Nivedhitha syedabusalma.shaik@gmail.com <p>Infertility affects approximately 10-15% of men and women worldwide, and it is influenced by a variety of factors. These include age, family history, nutrition, body weight, exercise habits, psychological stress, hormonal imbalances, and environmental factors. While infertility is often viewed as a physical condition, it also has profound emotional and psychological implications, impacting overall well-being.Individuals struggling with infertility, especially women, are more likely to experience mental health challenges, such as depression, anxiety, and stress. Infertile women often report a significantly lower quality of life compared to their fertile counterparts, with many experiencing feelings of inadequacy, grief, and isolation. About 23% of women facing infertility are diagnosed with anxiety disorders, highlighting the emotional toll the condition takes.The psychological impact is further intensified after failed fertility treatments like in vitro fertilization (IVF). Unsuccessful IVF attempts can lead to a sense of hopelessness, deepening depression, and anxiety, complicating the emotional landscape. Because of the mental health challenges associated with infertility, it is crucial to provide comprehensive care that includes emotional support. Addressing the psychological aspects of infertility alongside physical treatment can improve patients’ well-being, making it a vital part of holistic infertility management. Supporting emotional health is essential to help individuals cope with the emotional burden infertility brings.</p> 2024-10-04T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences https://pharmasprings.com/ijcpms/article/view/664 Development and bioavailability improvement of Resiquimod in the form of solid lipid nanoparticles 2024-11-25T13:24:31+0530 Arava sravanthi aravasravanthi01@gmail.com M Pradeep Kumar aravasravanthi01@gmail.com C Manjula aravasravanthi01@gmail.com B Jagadeesh Babu aravasravanthi01@gmail.com <p>The present study aims to develop Resiquimod's Solid Lipid Nanoparticles (SLNs) for topical drug delivery. To evaluate the physicochemical characterization of Resiquimod, lipids, polymers, surfactants &amp; other additives. Formulation &amp; Evaluation of SLNs for particle size analysis, Zeta potential, entrapment efficiency, polydispersity index (PDI), and % yield of produced SLNs. Based on the current studies, it can be said that Resiquimod solid lipid nanoparticles were effectively created and optimized. Hydrogels of prepared SLNs can be applied topically to treat skin conditions such as actinic keratoses (AKs). Different concentrations of lipids and surfactants were used to design SLNs. Mannitol showed much effectiveness as a Cryoprotectant. The drug's excipient Research on the compatibility of drugs, lipids, polymers, and their combinations using FTIR and DSC confirms that the drugs and excipients do not interact chemically. The Nanoparticles in the SLN droplets were intact, non-aggregated, and almost spherical according to scanning electron microscopy (SEM) pictures. The particle size of SLNs loaded with Resiquimod ranges from 208 to 503 nm. This could contribute to the SLNs' more extended blood circulation period. It was discovered that the PDI was less than 0.6. Adequate stability was demonstrated by the negative charge of the zeta potential in the formulation of SLNs. The results are encouraging and represent a novel contribution of Resiquimod SLNs in Topical Drug Delivery.</p> 2024-10-01T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences https://pharmasprings.com/ijcpms/article/view/665 Actd regulatory requirements for approving an anticancer drug (thioguanine) 2024-11-25T13:41:51+0530 Yasmin Asraf yasminasraf425@gmail.com Rajasekhar Sreerama yasminasraf425@gmail.com Audinarayana Nelavala yasminasraf425@gmail.com G Neelima yasminasraf425@gmail.com D Jothieswari yasminasraf425@gmail.com <table width="654"> <tbody> <tr> <td rowspan="3" width="483"> <p>This work makes document handling safer and more accessible. It can manage even more complex papers in addition to all the benefits. Using this work, a composite document or papers from several different document sources and formats can be assembled, updated, and published. Each document is treated as a single, identically organized document. BMR, Process Validation Record, Stability Study (including Accelerated &amp; Long Term Stability Study per Myanmar Zone Specification), Anticancer Drug Packing Requirements, and Certificate for Product Permission (covering all aspects from manufacturing to its packing &amp; registration) are among the required documents. It offers reliable scientific methods for determining the effectiveness, safety, and quality of medicinal items. It will assist in comprehending the documentation needs for drug registration in Myanmar.</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td width="0">&nbsp;</td> </tr> </tbody> </table> 2024-10-02T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences